Roche mulling quick filing for a tarnished Alzheimer’s drug as controversial Aduhelm OK electrifies the field — analyst
It’s increasingly unclear just how long Biogen will have the only major Alzheimer’s drug on the market.
According to a report from Jefferies, Roche has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
